Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant

• US 20050267440A1
• Filed: 06/01/2005
• Published: 12/01/2005
• Est. Priority Date: 06/01/2004
• Status: Abandoned Application

• Current Assignee: MicroCHIPS Inc.
• Original Assignee: MicroCHIPS Inc.
• Inventors: Lipka, Sara A., Santini, John T. Jr., Herman, Stephen J., Prescott, James H., Staples, Mark A., Kreiger, Timothy
• Application Number:
  US11/142,629
• Publication Number:
  US 20050267440A1
• Time in Patent Office: Days
• US Class Current: 604/501
• CPC Class Codes: A61B 5/03 Detecting, measuring or recording fluid pressure within the body other than blood pressure, e.g. cerebral pressure; Measuring pressure in body tissues or organs A61B5/205 takes precedence
• CPC Class Codes: A61B 5/076 Permanent implantations telemetry using implanted circuitry A61B5/0031; implanted stimulators for therapy A61N1/3605, A61N1/362, A61N1/372
• CPC Class Codes: A61B 5/14528 invasively
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1486 using enzyme electrodes, e.g. with immobilised oxidase
• CPC Class Codes: A61B 5/24 Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• CPC Class Codes: A61B 5/283 Invasive
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0097 Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips intradermal microneedle arrays A61K9/0021; MEMS in general B81B7/02
• CPC Class Codes: A61M 37/00 Other apparatus for introducing media into the body for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30; Percutany, i.e. introducing medicines into the body by diffusion through the skin salt baths A61H33/04
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
• CPC Class Codes: A61N 1/306 Arrangements where at least part of the apparatus is introduced into the body
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Methods and devices are provided for enhancing mass transport through any fibrous tissue capsule that may form around an implanted medical device following implantation. Methods and devices are also provided to enhance vascularization around the implanted device, which also will aid in mass transport to/from the device. The device preferably comprises multiple reservoirs containing (i) a drug formulation for short- or long-term, controlled drug delivery, (ii) sensors for sensing an analyte in the patient, or (iii) a combination thereof.

Claims

1. A method of enhancing the transport of drug from an implanted drug delivery device across a tissue capsule, the method comprising:

controllably releasing a drug formulation from a plurality of discrete reservoirs located in medical device implanted in a patient; and

controllably releasing an effective amount of a transport enhancer from said medical device implanted in a patient, to facilitate transport of the released drug formulation through a fibrous tissue capsule, if any, which exists around the device at the site of implantation.

2. The method of claim 1, wherein the release of the enhancing agent is from one or more reservoirs located in the device.

3. The method of claim 1, wherein the release of the enhancing agent is from a surface coating on the device.

4. The method of claim 1, wherein the release of the transport enhancer occurs concurrently with release of the drug formulation.

5. The method of claim 1, wherein the release of the transport enhancer occurs continuously.

6. The method of claim 1, wherein the drug formulation further comprises the transport enhancer, and the drug formulation and the transport enhancer are released from the same reservoirs.

7. The method of claim 1, wherein the transport enhancer comprises a solvent or co-solvent for the drug.

8. The method of claim 1, wherein the transport enhancer comprises a surfactant.

9. The method of claim 1, wherein the transport enhancer comprises dimethylsulfoxide or N-methylpyrrolidone.

10. The method of claim 1, wherein the drug molecules comprises charged molecules and the transport enhancer comprises ion-pairing counter-ions.

11. The method of claim 1, wherein the transport enhancer comprises molecules which dissolve or degrade components of the tissue capsule.

12. The method of claim 11, wherein the molecules comprise collagenase.

13. The method of claim 11, wherein the molecules comprise thrombin, fibrinolysin, hyaluronidase, or trypsin.

14. The method of claim 1, wherein device further includes means for mechanically driving the drug formulation out of the reservoir and through the tissue capsule.

15. The method of claim 14, wherein the means for mechanically driving the drug formulation comprises a piston, a water-swellable material, or a combination thereof.

16. The method of claim 1, wherein the device further comprises an angiogenic coating or angiogenic molecules for release.

17. The method of claim 16, wherein the angiogenic coating, angiogenic molecules for release, or both, comprise a vascular endothelial growth factor.

18. The method of claim 1, wherein the device further comprises an anti-inflammatory agent, which is released from the reservoirs or from a coating on the device or both from the reservoirs and the coating.

19. The method of claim 18, wherein the anti-inflammatory agent comprises dexamethasone.

20. A method of enhancing the transport of drug from an implanted drug delivery device and across a tissue capsule, the method comprising:

controllably releasing a drug formulation, which comprises charged drug molecules, from a plurality of discrete reservoirs of a medical device implanted into a patient, the release of the drug and the release of the enhancing agent being from one or more reservoirs located in the device; and

utilizing an electromotive method to enhance transport of the charged drug molecules through a tissue capsule, if any, surrounding the implanted medical device.

21. The method of claim 20, wherein the electromotive method comprises iontophoresis.

22. The method of claim 20, wherein an external surface of the medical device is charged by an electronic component therein, or thereon, creating a driving force effective to propel the drug molecules through a tissue capsule, if any, surrounding the implanted medical device.

23. A method of enhancing the transport of an analyte to a sensor device implanted in a patient, the method comprising:

controllably releasing an effective amount of a transport enhancer from the implanted sensor device, said device comprising a plurality of discrete reservoirs having sensors located therein.

24. The method of claim 23, wherein the device further comprises:

reservoir caps; and

means for rupturing said reservoir caps.

25. An implantable medical device comprising:

a body portion;

two or more reservoirs located in and defined by the body portion;

reservoir contents in the reservoirs; and

means for enhancing mass transport, of all or a portion of the reservoir contents or of an environmental component intended for contact with all or a portion of the reservoir contents, through any fibrous tissue capsule that may form around the device following implantation.

26. The device of claim 25, wherein the reservoir contents comprises a drug formulation.

27. The device of claim 25, wherein the reservoir contents comprises a sensor.

28. The device of claim 25, wherein the means for enhancing mass transport comprises a transport enhancer, an electromotive device, a positive displacement mechanism, or a combination thereof.

29. The device of claim 25, further comprising an angiogenic coating or angiogenic molecules for release.

30. The device of claim 29, wherein the angiogenic coating, angiogenic molecules for release, or both, comprise a vascular endothelial growth factor.

31. The device of claim 25, further comprising an anti-inflammatory agent, which is released from the reservoirs or from a coating on the device or both from the reservoirs and the coating.

32. An implantable device for testing drug or analyte transport through a tissue capsule, the device comprising:

a primary body having an outer surface, a perfusate fluid inlet, a perfusate fluid outlet, and a fluid conduit extending between the inlet and the outlet;

a substrate attached to the primary body;

at least one reservoir defined in and extending through the substrate, the reservoir having a first opening in the fluid conduit and a second opening which can be open to the outer surface of the device;

at least one reservoir cap covering the second opening of the reservoir;

means for selectively disintegrating or removing the reservoir cap.

33. The device of claim 32, further comprising a first flexible tubing connected to the perfusate fluid inlet, a second flexible tubing connected to the perfusate fluid outlet, and a means for flowing perfusate thorough the fluid conduit and the flexible tubings.

34. The device of claim 34, further comprising a semipermeable barrier structure blocking bulk fluid flow through one or both of the reservoir openings following reservoir cap disintegration or removal.